IMVT vs PRAX: Which Stock Is the Better Buy?
Immunovant, Inc. and Praxis Precision Medicines, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — IMVT vs PRAX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Immunovant, Inc. (IMVT) | Praxis Precision Medicines, Inc. (PRAX) | |
|---|---|---|
| Market cap | $6.6B | $6.8B |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-505.61M | $-303.27M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | — |
| Return on equity | -59.3% | -34.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full IMVT vs PRAX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open IMVT's full financials → Open PRAX's full financials →More comparisons
Frequently asked questions
Which is bigger, IMVT or PRAX?
Praxis Precision Medicines, Inc. is larger by market capitalization — $6.8B versus $6.6B.
Which grows faster, IMVT or PRAX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.